Rise Therapeutics advances Phase 1 trial for immuno-oncology candidate R-5780

Rise Therapeutics announced it completed the dose escalation portion of its Phase 1 clinical trial for R-5780, its lead immuno-oncology candidate. The study, which assesses R-5780's ability to reawaken anti-tumor immune responses in patients resistant to PD-1 inhibitors, will now move into dose expansion. This expansion phase will further evaluate the drug's safety, tolerability, and potential to enhance immune checkpoint inhibitor therapy.

The advancement of R-5780 into a dose expansion phase is a significant step in translating the company's novel immunotherapy approach into a potential treatment option for cancer patients. This progression relates directly to the company's pipeline and future commercial viability.